Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (352)	12/27/2000 8:21:36 PM
From: tom pope	Read Replies (2) \| Respond to of 2243

>>INCR already on it? << Tuck, you are a rational and sane observer of the biotech scene. Why is INCR down some 20-25%% since the ELN partnership announcement? Tax selling? Total trades today amounted to less the $120K. Somebody is reading the numbers 180 degrees away from what I see.

To: tuck who wrote (352)	1/1/2001 12:44:32 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

>> Per Doc Bones, feel 10x is more likely. << No question, an unreasonable objective. But, it got us thinking "leverage". Given some chatter on other threads..... one way to achieve good results in biotech investing is to find solid science, backed by patents, at a discount to their intrinsic value. IMO, that's the best way to invest in biotech, and it's certainly the most fun. Add to the fun by finding solid BIG science, backed by IP, at a discount. Then add a taste for leverage, a discounted potential for success on top of success, and you're off for a romp. And, as always, one company won't do. One must find a collection -- a basket -- of such suckers. Make sure that none of the components have a "Dave and Sam show", but the method does allow for profit in the face of big mistakes. Cash rich, cash poor, yada, yada.